Meige综合征的A型肉毒毒素治疗

近年研究证实 ,Ａ型肉毒毒素能有效地治疗局部肌张力不全。Ｍｅｉｇｅ综合征是局限性肌张力不全的一种 ,我们用国产Ａ型肉毒毒素治疗Ｍｅｉｇｅ综合征共 18例 ,均获得满意效果。1　资料和方法 :　本组确诊为Ｍｅｉｇｅ综合征的患者 18例。采用国产Ａ型肉毒毒素 ,根据不同的症状     

A型肉毒毒素治疗Meige综合征

ｅｉｇｅ综合征亦称特发性眼睑痉挛—口下颌肌张力异常综合征 ,临床不甚多见 ,好发于中、老年人。一年多来我们应用Ａ型肉毒毒素 (ＢＴＸ Ａ)局部注射治疗Ｍｅｉｇｅ综合征 12例 ,取得满意疗效 ,现报告如下。1　临床资料本组 12例中 ,男 4例 ,女 8例 ,年龄 4 4～ 6 7岁 ,平均年     

A型肉毒杆菌毒素治疗眼睑痉挛及面肌痉挛临床研究

应用Ａ型肉毒杆菌毒素局部注射治疗眼睑痉挛９例及面肌痉挛３３，例完全缓解者分别为６例及３１例，明显缓解者分别为３例及２例，所有病例均有效，总有效期分别为４～２０周（平均１４周）及１６～３４周（平均２２周）。局部副反应轻微、短暂，无全身反应及过敏反应，且操作简单。认为Ａ型肉毒杆菌毒素是一种安全有效的生物制剂，该方法可作为治疗眼睑痉挛及面肌痉挛的新方法．     

A型肉毒毒素加用抗痉挛药治疗Meige综合征的疗效观察

目的 观察A型肉毒毒素及抗痉挛药物联合治疗Meige综合征的疗效。方法 对30例Meige综合征患者应用A型肉毒毒素对痉挛肌肉多点注射，每点0．1－0.2ml(2.5-5U)，同时服用抗乙酰胆碱和苯二氮Zhuo类药物。结果 A型肉毒毒素对眼睑痉挛的治疗，4－5天症状缓解，1个星期明显缓解，2个星期疗效达最高峰。有效率100％。有效作用时间为10－24周，平均11．7周。而抗乙酰胆碱和苯二氮Zhuo类药物对口下颌肌张力障碍的治疗效果比较明显，可以有效的缓解患者的磨牙咂嘴和舌不自主伸缩等症状。结论 A型肉毒毒素和抗乙酰胆碱及苯二氮Zhuo类药物联合应用是治疗Meige综合征的一种安全、有效、简便的方法。     

A型肉毒毒素治疗局限性肌张力障碍与面肌痉挛

采用美国Ａｌｅｒｇａｎ公司产Ａ型肉毒毒素Ｂｏｔｏｘ局部注射治疗痉挛性斜颈１０例，偏侧面肌痉挛１９例，眼睑痉挛７例，Ｍｅｉｇｅ综合征３例，共３９例局限性肌肉痉挛患者。在治疗后随访５～１３个月。使用Ｔｓｕｉ量表对治疗前后痉挛性斜颈病例进行病情评估，用Ｃｏｈｅｎ和Ａｌｂｅｒｔ量表对其余病例进行病情评估。结果表明治疗后病情的好转是显著的（Ｐ＜０．００１）。患者中症状明显改善者占８２．１％，疗效持续６～２６周，可在３至６个月后重复注射，重复取得疗效。其中１２例出现轻微的并发症，包括２例眼睑下垂，７例面肌力弱，１例视力模糊，１例吞咽困难以及１例体重下降。以上１２例除体重下降者外，均在数周内恢复。初步研究表明，局部注射Ａ型肉毒毒素Ｂｏｔｏｘ，如在有经验医师的指导下，必要时在肌电图监视下进行，确为一种有效、安全、简便易行的治疗手段，能在一段时间内缓解甚至消除肌肉痉挛及相关症状。可望在局限性肌张力障碍和面肌痉挛或其它肌张力过高的疾病中，开辟一个新的治疗领域。     

肉毒毒素A治疗Meige综合征

肉毒毒素Ａ治疗Ｍｅｉｇｅ综合征黄新民Ｍｅｉｇｅ综合征又称睑痉挛、口下颌肌张力障碍综合征，１９１０年首先由Ｍｅｉｇｅ报道，是成年起病的一种变形性肌张力障碍，主要为睑痉挛和口面部异常运动。应用Ａ型肉毒毒素（ＢＴＸＡ）治疗此病是８０年代治疗学上的一个新进展...     

A型肉毒毒素治疗局限性肌肉痉挛的临床研究

目的　观察A型肉毒毒素治疗偏侧面肌痉挛、眼睑痉挛及Meige综合征的疗效。方法　对 40例偏侧面肌痉挛、9例眼睑痉挛、1例Meige综合征进行面部肌肉局部多点注射A型肉毒毒素 ,评价其治疗效果。结果　 40例偏侧面肌痉挛者 ,完全缓解 1 5例 (38% ) ,明显缓解2 4例 (60 % ) ,1例无效 ;9例眼睑痉挛者 ,4例完全缓解 ,4例明显缓解 ,1例无效 ;1例Meige综合征部分缓解 ,总有效率达 96 %。起效时间平均 3天 ,缓解时间平均 3 5个月。局部副反应轻微、短暂 ,无全身反应及过敏反应。结论　A型肉毒毒素局部肌肉注射是治疗局限性肌肉痉挛的一种安全、有效的治疗方法。     

局部注射A型肉毒毒素治疗Meige综合征

目的 观察A型肉毒毒素(BTX—A)治疗Meige综合征，(眼睑痉挛-口颌肌张力障碍综合征)的疗效。方法 用A型肉毒毒素对17例Meige综合征行面部肌肉局部多点注射，分析其治疗结果。结果 17例中完全缓解者9例，明显缓解者5例，部分缓解者2例，无效1例。总有效率94％。起效时间数小时至3天，疗效持续时间3～6个月。局部副反应轻微、短暂，无全身反应及过敏反应。结论 A型肉毒毒素是治疗Meige综合征最有效的方法。     

A型肉毒毒素治疗面肌、眼睑痉挛156例临床观察

目的 探讨A型肉毒毒素治疗面肌，眼睑痉挛及Meige综合征的疗效。方法 采用A型肉毒毒素局部注射治疗偏侧面肌痉挛102例。眼睑痉挛41例及Meige综合征13例。并使用Cohen和Albert量表进行评估。结果 症状完全缓解占51.3%。明显改善占37.8%。部分改善占10.9%。疗效平均持续约3-6个月。复发者重复注射仍有效，出现眼睑闭合不全，面肌无力，眼睑下垂共58例，均恢复。结论 局部注射A型肉毒毒素确为一种安全有效。简便易行的治疗面肌。眼睑痉挛及Meige综合征的方法。     

A型肉毒毒素治疗面肌痉挛、眼睑痉挛疗效观察

目的观察A型肉毒毒素治疗面肌、眼睑痉挛的疗效。方法采用A型肉毒毒素局部注射治疗偏侧面肌痉挛51例、眼睑痉挛8例,并使用Cohen和Albert量表对疗效进行评估。结果31例(52.5%)症状完全缓解,22例(37.2%)明显改善,6例(10.1%)部分改善,疗效平均持续约9～33周,复发者重复注射仍有效。不良反应可出现眼睑闭合不全、面肌无力、眼睑下垂等共18例,均在4周内恢复。结论局部注射A型肉毒毒素确为一种安全有效的治疗面肌、眼睑痉挛的方法。     

重复局部注射A型肉毒毒素治疗局限性肌张力障碍长期疗效观察

目的研究重复局部注射A型肉毒毒素治疗偏侧面肌痉挛、眼睑痉挛、Meige's综合征、痉挛性斜颈的长期疗效及维持时间,有无剂量增加趋势。方法用A型肉毒毒素对241例患者重复小剂量局部多点注射,随访治疗10年,将6轮次治疗疗效以及剂量、疗效维持时间、不良反应进行比较分析。结果各轮次总有效率分别为98.7%、98.9%、99.3%、100%、100%、100%。作用持续(20±3)周,平均剂量40U,各轮间疗效、平均剂量、作用持续时间均无显著差异(P>0.05)。结论重复局部注射治疗局限性肌张力障碍长期疗效稳定,作用持续时间相似,维持疗效无需增加剂量,局部不良反应轻微短暂。     

Local insulin injection improves median nerve regeneration in NIDDM patients with carpal tunnel syndrome

It has been suggested that insulin has an effect on nerve regeneration similar to that of nerve growth factor (NGF). Therefore, we aimed to evaluate the effectiveness of local insulin injection on median nerve in patients with non-insulin-dependent diabetes (NIDDM) mellitus who have mild-to-moderate carpal tunnel syndrome (TS). We carried out a prospective, randomized, double-blind, placebo-controlled study in these patients. At the baseline, 20 mg methylprednisolone was injected directly into the carpal tunnel in all patients [n=43 (62 hands)]. A week after prednisolone, the placebo or NPH insulin (12 U) was injected into the carpal tunnel weekly for 7 weeks. The patients were followed up for 23 weeks. A significant improvement in mean median nerve motor distal latency (MNMDL), median nerve sensory velocity (MNSV), and global symptom score (GSS) occurred in both groups (with the exception of mean MNMDL in the placebo group). A more significant improvement in the mean MNMDL, MNSV, and GSS was observed in the insulin group when compared with the placebo group. This study suggests that local insulin treatment may be of great potential benefit in the improvement of nerve functions in NIDDM patients with mild-to-moderate CTS who opt for conservative treatment.     

Remote Effects of Local Injection of Botulinum Toxin Type A

Objective To assess the seventy and temporal profile of remote effects of botulinum toin type A, BTX-A (Botox from Allergan Inc.,USA and CBTX-A made by Lanzhou Biological Products Institute, China ) injected locally on neuromuscular transmission. Background Recently the local injection of BTX-A has been accepted as a breakthrough in the treatment of a variety of spasmodic disorders, and remote effects of BTX-A on the neuromuscular transmission are concemed. Methods Fourty patients who had enrolled in a prospective open study with Botox or CBTX-A for their movement disorders were studied, 18 cases with Botox and 22 cases with CBTX-A. SFEMG in the extensor digitorum communis muscle or tibialis anterior muscle was performed before and 2-3weeks, 5-8weeks, 4-5 months after injection of Botox or CBTX-A, totally 119 times. Results The significant increase of jitter was demonstrated 2-3weeks after injections in both groups and MCD was in direct proportion to dose of injections.Fiber density value increased at the same time or later and still existed until 4-5 months after injections. Conclusion There are subclinical effects on neuromuscular transmission of remote uninjected muscles after injections of Botox and CBTX A, which indicates that the toxin spread remotely from the site of injection.     

偏侧面肌痉挛和良性特发性眼睑痉挛的临床与治疗特点

目的 探讨偏侧面肌痉挛(HFS)和良性特发性眼睑痉挛(BEB)的临床特点、治疗现状以及对A型肉毒毒素(BTX-A)治疗的反应.方法 对2013年4~10月在武汉大学人民医院神经内科门诊就诊的HFS患者和BEB患者进行调查,其中HFS患者110例,BEB患者90例.所有的患者均接受了BTX-A局部注射治疗.注射后2周左右复诊,在每周二下午的专病门诊随访,并记录BTX-A的疗效持续时间.结果(1)入组200例患者中,BTX-A治疗起效时间0~30 d(中位数4 d),疗效持续时间2~128周(中位数16周),总有效率96.9%.HFS患者症状明显好转(完全和明显缓解)占99.3%,BEB患者占90.2%.总的来说,BEB患者的疗效持续时间[(13.6±5.5)周]与HFS患者[(20.3±10.2)周]相比较短.HFS患者所用BTX-A剂量[(53.2±15.8)U]较BEB患者[(74.8±20.2)U]少.(2)BTX-A注射(70.9%)、针灸(68.2%)和口服药(65.5%)是HFS患者曾经选择的最多的非手术治疗方法.针灸和口服药大部分效果不好而自行停用.BTX-A注射(88.9%)、口服药(86.7%)和眼轮匝肌切割术(31.1%)是BEB患者曾经选择的最多的治疗方法,但患者均反映手术无效.结论 HFS和BEB是运动障碍门诊最常见的两种疾病,BTX-A治疗HFS和BEB安全、有效,对HFS效果更好,BEB患者需要更频繁的注射,其面部肌张力障碍的治疗更具挑战性.     

A型肉毒素治疗睑肌痉挛的长期疗效与安全性

目的:探讨A型肉病毒素(dysport)治疗睑肌痉挛的长期疗效及安全性。方法:回顾性分析46例原发性睑肌痉挛患者于第1、3、5年接受dysport注射的剂量、起效时间、疗效持续时间、症状改善率不良反应。结果:46例患者第1、3、5年中位症状改善率分别为90%、85%及80%,治疗5年后仍有93.48%的患者改善率50%,且疗效持续8周以上。第1、3、5年起效时间分别为4、5和7 d,有延长趋势;疗效持续时间稳定维持在12周;治疗剂量略有下降,但无显著性差异。主要不良反应为睑下垂、疼痛烧灼感、复视及局部血肿,1周内自行消失,无过敏及全身不良反应。结论:dysport局部注射治疗睑肌痉挛安全,疗效持久,能最大程度地改善局部痉挛症状,可能成为治疗睑肌痉挛的首选方法。     

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm

IncobotulinumtoxinA (Xeomin^®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous studies evaluated single sets of incobotulinumtoxinA injections for the treatment of blepharospasm. Individualized injection intervals and other potential determinants of efficacy and safety need to be evaluated in a prospective, longitudinal study. Subjects with blepharospasm who completed a ≤20 weeks double-blind, placebo-controlled main period entered a ≤69 weeks open-label extension period (OLEX) and received ≤5 additional incobotulinumtoxinA treatments at flexible doses (≤50 U per eye) and flexible injection intervals (minimum of 6 weeks). Outcome measures included Jankovic Rating Scale (JRS) (sumscore, severity subscore and frequency subscore), Blepharospasm Disability Index, and adverse events. All 102 subjects who completed the main period entered the OLEX; 82 subjects completed the study, 56 received the maximum five injections. From each injection visit to a control visit 6 weeks later, investigator-rated JRS sumscores and subscores, and patient-rated Blepharospasm Disability Index were significantly improved (p ≤ 0.001 for all). All scores were still significantly improved at trial termination compared with the first injection visit (p < 0.05 for all). The most frequently reported adverse events were eyelid ptosis (31.4 %) and dry eye symptoms (17.6 %). The injection interval had no impact on the incidence of adverse events (post hoc analysis). No subject developed neutralizing antibodies during the study. Repeated incobotulinumtoxinA injections, administered at flexible doses and injection intervals from 6 to 20 weeks according to subjects’ needs, provide sustained efficacy in the treatment of blepharospasm with no new or unexpected safety risks.     

Pretarsal application of botulinum toxin for treatment of blepharospasm.

The response to botulinum toxin type A was compared after two injection techniques in 45 patients with blepharospasm. Initially, patients were treated according to a triple injection technique; two injections into the upper eyelid and one injection into the lower eyelid. Subsequently, without altering the dose, the same patient group received two further injections into the pretarsal portion of the orbicularis oculi muscle of the upper lid. Triple injections were given in 227 treatments, of which 81% were successful. Mean duration of benefit was 8.5 weeks. Additional pretarsal injections were given in 183 treatment sessions. The number of successful treatments significantly increased, to 95% (P < 0.001), and the mean duration of benefit increased to 12.5 weeks (P < 0.001). Ptosis occurred significantly less often after pretarsal injections (P < 0.01). Patients with combined blepharospasm and involuntary levator palpebrae inhibition responded better to the pretarsal injection technique.